Welcome!

News Feed Item

Spinal Stenosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Spinal Stenosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html

Spinal Stenosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Spinal Stenosis Global Clinical Trials Review, H2, 2014" provides data on the Spinal Stenosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Spinal Stenosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Spinal Stenosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Spinal Stenosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Spinal Stenosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Spinal Stenosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Spinal Stenosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Sucampo Pharmaceuticals, Inc. 31
Clinical Trial Overview of Sucampo Pharmaceuticals, Inc. 31
Mesoblast Limited 32
Clinical Trial Overview of Mesoblast Limited 32
Zimmer Holdings, Inc. 33
Clinical Trial Overview of Zimmer Holdings, Inc. 33
United Therapeutics Corporation 34
Clinical Trial Overview of United Therapeutics Corporation 34
Nissan Chemical Industries, Ltd. 35
Clinical Trial Overview of Nissan Chemical Industries, Ltd. 35
LTT Bio-Pharma Co., Ltd. 36
Clinical Trial Overview of LTT Bio-Pharma Co., Ltd. 36
KT&G Corporation 37
Clinical Trial Overview of KT&G Corporation 37
Kaken Pharmaceutical Co., Ltd. 38
Clinical Trial Overview of Kaken Pharmaceutical Co., Ltd. 38
Biomet, Inc. 39
Clinical Trial Overview of Biomet, Inc. 39
Clinical Trial Overview of Top Institutes / Government 40
Seoul National University Hospital 40
Clinical Trial Overview of Seoul National University Hospital 40
Keio University 41
Clinical Trial Overview of Keio University 41
Hamamatsu University School of Medicine 42
Clinical Trial Overview of Hamamatsu University School of Medicine 42
University of Pittsburgh 43
Clinical Trial Overview of University of Pittsburgh 43
Vanderbilt University 44
Clinical Trial Overview of Vanderbilt University 44
Leiden University Medical Center 45
Clinical Trial Overview of Leiden University Medical Center 45
Yonsei University 46
Clinical Trial Overview of Yonsei University 46
Dartmouth-Hitchcock Medical Center 47
Clinical Trial Overview of Dartmouth-Hitchcock Medical Center 47
Emory University 48
Clinical Trial Overview of Emory University 48
Federal University of Sao Paulo 49
Clinical Trial Overview of Federal University of Sao Paulo 49
Five Key Clinical Profiles 50
Appendix 68
Abbreviations 68
Definitions 68
Research Methodology 69
Secondary Research 69
About GlobalData 70
Contact Us 70
Disclaimer 70
Source 70

List of Tables

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Spinal Stenosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Spinal Stenosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sucampo Pharmaceuticals, Inc., 2014* 31
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mesoblast Limited, 2014* 32
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Zimmer Holdings, Inc., 2014* 33
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by United Therapeutics Corporation, 2014* 34
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Nissan Chemical Industries, Ltd., 2014* 35
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by LTT Bio-Pharma Co., Ltd., 2014* 36
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by KT&G Corporation, 2014* 37
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaken Pharmaceutical Co., Ltd., 2014* 38
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biomet, Inc., 2014* 39
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 40
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Keio University, 2014* 41
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamamatsu University School of Medicine, 2014* 42
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 43
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014* 44
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Leiden University Medical Center, 2014* 45
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Yonsei University, 2014* 46
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Dartmouth-Hitchcock Medical Center, 2014* 47
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014* 48
Spinal Stenosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014* 49

List of Figures

Spinal Stenosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Spinal Stenosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Spinal Stenosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Spinal Stenosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Spinal Stenosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Spinal Stenosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Spinal Stenosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Spinal Stenosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Spinal Stenosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Spinal Stenosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Spinal Stenosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Spinal Stenosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Spinal Stenosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Spinal Stenosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Spinal Stenosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Spinal Stenosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Spinal Stenosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 69


To order this report: Spinal Stenosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280947/Spinal-Stenosis-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
"Qosmos has launched L7Viewer, a network traffic analysis tool, so it analyzes all the traffic between the virtual machine and the data center and the virtual machine and the external world," stated Sebastien Synold, Product Line Manager at Qosmos, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
"We are a leader in the market space called network visibility solutions - it enables monitoring tools and Big Data analysis to access the data and be able to see the performance," explained Shay Morag, VP of Sales and Marketing at Niagara Networks, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.